912999-79-2

Basic information

• Product Name: 5-chloroisoindoline hydrochloride
• Synonyms: 5-Chloro-2,3-dihydro-1H-isoindole hydrochloride;5-CHLOROISOINDOLINE HCL
• CAS NO: 912999-79-2
• Molecular Formula: C₈H₈ClN*ClH
• Molecular Weight: 190.06976
• Mol File: 912999-79-2.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: 5-chloroisoindoline hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 5-chloroisoindoline hydrochloride(912999-79-2)
• EPA Substance Registry System: 5-chloroisoindoline hydrochloride(912999-79-2)

Safety Data

• Hazardous Substances Data: 912999-79-2(Hazardous Substances Data)

Usage

General Description

5-Chloroisoindoline hydrochloride is a chemical compound that consists of a chlorinated isoindoline ring structure. It is commonly used in organic synthesis and medicinal chemistry as a versatile building block for creating various pharmaceutical and agrochemical products. 5-Chloroisoindoline hydrochloride has the potential to exhibit a wide range of biological activities, including antitumor, antiviral, and antibacterial properties. As a hydrochloride salt, 5-Chloroisoindoline is water-soluble and stable under normal conditions, making it a valuable reagent for research and development in the pharmaceutical industry. Additionally, it has been studied for its potential use in the synthesis of novel drug candidates and bioactive compounds.

Upstream product

• 127168-77-8 5-chloro-2-p-tosylisoindoline 
• 127168-76-7 5-chloro-2,3-dihydro-1H-isoindole 

Downstream Products

• 1240325-48-7 C₃₂H₂₈ClNO₃ 

Relevant articles and documents

Discovery of (2,4-Dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1- ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design

Inhibitors of the molecular chaperone heat shock protein 90 (Hsp90) are currently generating significant interest in clinical development as potential treatments for cancer. In a preceding publication (DOI: 10.1021/jm100059d) we describe Astex's approach to screening fragments against Hsp90 and the subsequent optimization of two hits into leads with inhibitory activities in the low nanomolar range. This paper describes the structure guided optimization of the 2,4-dihydroxybenzamide lead molecule 1 and details some of the drug discovery strategies employed in the identification of AT13387 (35), which has progressed through preclinical development and is currently being tested in man.

PHARMACEUTICAL COMBINATIONS

The invention provides combinations comprising (or consisting essentially of) one or more ancillary compound(s) and a compound of the formula (I): or salts, tautomers, solvates and N-oxides thereof; wherein R1 is hydroxy or hydrogen; R2 is hydroxy; methoxy or hydrogen; provided that at least one of R1 and R2 is hydroxy; R3 is selected from hydrogen; halogen; cyano; optionally substituted C1-5 hydrocarbyl and optionally substituted C1-5 hydrocarbyloxy; R4 is selected from hydrogen; a group -(O)n-R7 where n is 0 or 1 and R7 is an optionally substituted acyclic C1-5 hydrocarbyl group or a monocyclic carbocyclic or heterocyclic group having 3 to 7 ring members; halogen; cyano; hydroxy; amino; and optionally substituted mono- or di-C1-5 hydrocarbyl-amino; or R3 and R4 together form a monocyclic carbocyclic or heterocyclic ring of 5 to 7 ring members; and NR5R6 forms an optionally substituted bicyclic heterocyclic group having 8 to 12 ring members of which up to 5 ring members are heteroatoms selected from oxygen, nitrogen and sulphur. The combinations have activity as Hsp90 and/or glycogen synthase kinase-3 and/or cyclin dependent kinase and/or aurora kinase inhibitors.

PHARMACEUTICAL COMPOUNDS

The invention provides the use of a compound for the manufacture of a medicament for the treatment of pain, wherein the compound is a compound of the formula (Vl): or a salt, solvate, tautomer or N-oxide thereof; wherein the bicydic group: is selected from the structures C1, C5 and C6: wherein n, R1, R2a, R3, R4a, R8 and R10 are as defined in the claims. The invention also provides the use of a compound of the formula (Vl) for the manufacture of a medicament for the prophylaxis or treatment of a fungal, protozoal, viral or parasitic disease state or condition (other than a disease state or condition due to Plasmodium falciparum) or for use in the prophylaxis or treatment of Ewing's sarcoma, atherosclerosis or lupus erythematosus